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&p.1:Abstract The accuracy of cytogenetic analyses of hu-
man solid cancers has improved enormously over the
past decade by the introduction and refinement of DNA
in situ hybridization (ISH) techniques. This methodology
can be applied to cells in the interphase state, thereby
making it an excellent tool for the delineation of chro-
mosomal aberrations in solid tumors. The use of non-iso-
topic ISH to intact and disaggregated cancer specimens
will be discussed, as well as comparative genomic hy-
bridization (CGH) with tumor-derived DNAs. In this re-
view we will focus on hybridocytochemical interphase
approaches for the detection of chromosomal changes in
frequently occurring human epithelial malignancies, e.g.,
breast, lung, and prostate carcinomas. We will further
discuss the use of ISH procedures for the genetic analy-
sis of precursor conditions leading to invasive carcino-
mas. Knowledge concerning these precancerous condi-
tions is increasing, and its importance in cancer preven-
tion has been recognized. Interphase cytogenetics by
ISH, as well as CGH, with DNAs derived from microdis-
sected, precancerous, dysplastic tissue areas will in-
crease our understanding of these lesions, both at the in-
vestigative and diagnostic levels.&bdy:
Introduction
In 1914, Theodor Boveri concluded in his classical work
entitled ‘‘Zur Frage der Entstehung maligner Tumoren’’
that cancer is a genetic disease, caused by clonal chro-
mosomal changes (Boveri 1914). Most of Boveri’s state-
ments eventually turned out to be true. However, it was
not until 1960 that the first consistent chromosomal ab-
normality was found in human tumor cells [i.e., the Phil-
adelphia (Ph) chromosome in chronic myelogenous leu-
kemia; Nowell and Hungerford 1960]. With the subse-
quent introduction and continuous improvement of chro-
mosome banding techniques, allowing reliable recogni-
tion of each chromosome and of sub-chromosomal struc-
tures, a large-scale search for specific karyotypic abnor-
malities could be initiated. Initially, most information
was obtained from leukemia and lymphoma (Sandberg
1990). In two decades a vast amount of detailed informa-
tion on the occurrence of chromosomal abnormalities in
human cancer has been accumulated (see Sandberg
1990; Mitelman 1994 for reviews) and acquired clonal
chromosomal aberrations have indeed been demonstrated
to be a characteristic feature of tumor cells (Nowell
1976; Heim and Mitelman 1987; Sandberg 1990). The
general view is that tumor initiation and progression is a
multistep process, caused by an accumulation of genetic
aberrations resulting in the activation of oncogenes
and/or inactivation of tumor suppressor genes (Knudson
1971; Vogelstein et al. 1988; reviewed by Bishop 1991).
In the last decade, precancerous lesions, such as large
bowel adenomas or cervical dysplasias, have attracted
much attention for their role in malignant transformation
to invasive cancer (Rosai 1996). These precursor lesions
have currently established their importance in cancer
prevention and surveillance.
In situ hybridization and comparative genomic 
hybridization of epithelial neoplasms
Although solid tumors are much more frequent than he-
matological neoplasms, much less is known about the
cytogenetic aberrations that characterize them. Mostly
technical problems have for a long time hampered the
acquisition of cytogenetic data on solid tumors (Sand-
berg 1990). Solid tumor biopsies yield low numbers of
viable cells, have a low mitotic index, and frequently
contain non-neoplastic cells. Furthermore, the quality of
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metaphases is relatively poor. Therefore, interphase ap-
proaches, both at molecular and cytological levels, are
better equipped to disclose genetic changes occurring in
human epithelial cancers (Table 1) and their precursor le-
sions (Table 2) (see also Alers and van Dekken 1996,
and references therein). In this section we will review the
literature concerning interphase DNA in situ hybridiza-
tion (ISH), also termed interphase cytogenetics, as well
as comparative genomic hybridization (CGH) of fre-
quently occurring human epithelial neoplasms. In Figs.
1–3, examples (esophageal and prostatic cancer) are
shown of ISH (Fig. 1) and CGH (Fig. 2) of invasive can-
cers and their precancerous conditions (Fig. 3).
Lung cancer
In the literature, a subdivision is often made between
small cell lung cancers (SCLCs) and non-small cell lung
cancers (NSCLCs), the latter comprising squamous cell
carcinoma and adenocarcinoma. Interphase cytogenetics
on paraffin sections of lung tumors by non-isotopic ISH
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Table 1 Genetic alterations in frequently occurring human epithe-
lial cancers (Alers and van Dekken 1996). (LOH Loss of heterozy-
gosity, ISH in situ hybridization, CGH comparative genomic hy-
bridization, SCLC small cell lung cancer, NSCLC non-small cell
lung cancer, i isochromosome) &/tbl.c:&tbl.b:
Organ Karyotyping LOH ISH CGH
Lung (SCLC) −3p, −5, −5q, −13, 3p, 5q, 13q, 17p N-myc amplification Loss of 3p, 5q, 13q, 17p;
−13q, −17p gain of 3q, 5p, 8q, Xq
Lung (NSCLC) −3p, −6p, +7, +7p, 3p, 8p, 9p, 11pq, +7, −17 Loss and gain of several
−9p, −11p, −17p, −Y 13q, 17p loss of p15/p16 chromosomal sequences
Head and neck −3p, i(5p), i(8q), −8p 3p, 8p, 9pq, 11q int-2/hst-1 amplifi- Loss of 3p, 5q, 8p, 9p;
−10p, 11q13, −18q, −Y cation at 11q13 gain of 3q, 5p, 8q, 11q
Esophagus −1p, −4, 11p13, +20, −Y 5q, 9p, 13q, 17p +8, −17, −Y Loss of 8p, 9p, 16, 17;
gain of 8q, 20
Colorectum −1p, +7, −8p, i(8q), 5q, 8p, 17p, 18q +7, +8, −18 Loss of 9p, 17, 18q;
−17, −17p, −Y gain of 7, 8q, 13, 20q
Prostate +7, −7q, −8p, −10q, −Y 6q, 7q, 8p, 10pq, +7, −8, +8, −10, Loss of 6q, 8p, 13q, 16q;
13q, 16q, 18q −18, −Y gai of 7p, 7q, 8q, Xq
Bladder +7, −9, −11p 3p, 9pq, 11p, 13q, +1, +7, −9, +11, −17p, Loss of gain of several
17p amplification erbB-2 chromosomal sequences
Kidney −3p, −5q, −6, +7, −14, 3p, 5q, 6p, 8p, 9p, −1, +7, +17, −17, −Y Loss of 1, 2, 3p, 9p, Y;
−14q, −Y 14q, 17pq, 21q gain of 1q, 5q, 7, 16p
Breast i(1q), −1q, −3p, −6q, 1pq, 3p, 6q, 7q, 8p, 9p, +1, +7, −17p, Loss of 17p, 22q;
+7, +18, +20 11p, 13q, 16q, 17pq, 18q amplification erbB-2 gain of 1q, 8q, 17q, 20q
Ovary −8, +12, −13, −14, 3p, 11p, 13q, 17pq +1, +7, +8, +11, Loss of 16q, 17pg;
−17, −22, −X +11q, +12p, −17, −20, gain of 3q, 8q, 12p, 20q
&/tbl.b:
Table 2 Genetic alterations,
detected by various methods, in
defined precursor lesions of hu-
man epithelial cancers. [Meta-
plasia Transformation from
respiratory into stratified squa-
mous epithelium, DCIS ductal
carcinoma in situ, IN intra-
epithelial neoplasia of P pros-
tate, C uterine cervix, O oral
mucosa, E esophagus, metapla-
sia (Barrett) transformation
from stratified squamous into
columnar epithelium] &/tbl.c:&tbl.b:
Organ Carcinoma Precursor Aberrations
Lung (bronchus) Squamous cell ca. Metaplasia −3p, −5q, +7, −9p, −17p
Colon Adenocarcinoma Adenomatous polyp −1p, −5q, +7, +13, −14, −15,
−17p, −18, −18q, +20, −21
Breast Adenocarcinoma DCIS −1p, +1q, −6q, −7p, −8p, −9p, −11p,
−13q, −16q, −17p, −17q, +17q, +20q
Prostate Adenocarcinoma PIN −8p, −Y
Ovary Adenocarcinoma Borderline tumor +6, +7
Uterine cervix Squamous cell ca. CIN −5p
Head and neck Squamous cell ca. Metaplasia/OIN −9p
Esophagus Squamous cell ca. EIN −9q
Esophagus Adenocarcinoma Metaplasia (Barrett) −5q, −9p, −17p, −Y
&/tbl.b:
Fig. 1a–f Interphase in situ hybridization (ISH) of human epithe-
lial cancers. a–c Esophageal cancer (Barrett’s adenocarcinoma). a
Hematoxylin-eosin stained section, showing tumor cells (T), infil-
trating the smooth muscle layer (M) of the esophageal wall. b ISH
with the chromosome 7-specific centromeric DNA probe to a rou-
tinely processed, formalin-fixed, paraffin-embedded tissue section
of the same region. The ISH-related spots were visualized with
immunoperoxidase/diaminobenzidine (black); hematoxylin was
used as a counterstain (gray). Many cancer cell nuclei show ane-
usomic ISH spot numbers (a few are arrowed). c Same area of a
consecutive tissue section, showing ISH with a chromosome 17
DNA probe. Many cancer cell nuclei with 0 or 1 spot are seen, il-
lustrating loss of this chromosome. d–f Prostate cancer (bone me-
tastasis). d ISH with the chromosome 1-specific centromeric DNA
probe to a routinely processed, formalin-fixed, paraffin-embedded
tissue section of a bone metastasis of prostatic adenocarcinoma. e
Same tumor area on a consecutive section: ISH with a chromo-
some 8-specific centromeric DNA probe. Many tumor cell nuclei
display aneusomy, indicating gain of this chromosome (compare
with d). f Same area. Y-ISH, revealing loss of chromosome Y in
the cancer cells, but not in stromal cells (arrows). A 40× objective
was used, except for a (20×) &/fig.c:
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was also performed by Kim et al. (1993). ISH data were
found to correlate with the DNA index, derived from im-
age analysis of Feulgen-stained nuclei. However, in
some cases, chromosome 7 or 17 was either over- or un-
derrepresented compared with the DNA index. Fluores-
cence ISH (FISH) analysis of a SCLC cell line elucidat-
ed the origin of homogeneously staining regions (HSRs;
Dietzsch et al. 1994). These authors found the amplified
region to contain the N-myc gene. Recently, the copy
number of p15 and p16/MTS1, both located at
9p21–p22, was determined by double-color FISH analy-
sis of cell suspensions of 18 primary NSCLCs, using a
P1 (phage) contig probe (Xiao et al. 1995). Co-deletion
of p15 and p16 was found in 15 of 18 NSCLCs. It was
concluded that p15 and p16 are deleted and/or mutated
in most primary NSCLCs.
A CGH study of 13 primary SCLCs was performed
by Ried et al. (1994). Losses of chromosome arms 3p,
5q, 10q, 13q, and 17p were detected, as well as DNA
gains of 3q, 5p, 8q, and 17q. The most frequently ampli-
fied site was 19q13.1. Further, a CGH study of SCLC
cell lines by Levin et al. (1994) revealed increases in
DNA sequences at regions 1p22 (L-myc), 2p24–p25 (N-
myc), 5p, 8q24 (c-myc), and Xq26. Decreases were
found at 3p, 10q26, 13q14 (Rb) 16p11, 17p13 (p53), and
22q12–q13. The results, described above, were con-
firmed in recent investigations on larger panels of tumors
(Levin et al. 1995; Petersen et al. 1997).
Head and neck cancer
Head and neck tumors consist mostly of squamous cell
carcinomas (HNSCCs). Numerical aberrations of chromo-
some 17 were investigated in cell suspensions, derived
from four oral tumors, by FISH with centromeric probes
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Fig. 2a, b Comparative ge-
nomic hybridization (CGH) of
human epithelial cancers. A
Esophageal cancer (Barrett’s
adenocarcinoma): CGH of an
archival, formalin-fixed, paraf-
fin-embedded Barrett’s adeno-
carcinoma (region shown in
Fig. 1a). The chromosomal
ideograms are shown together
with the ratio profiles and the
digitized fluorescent images of
four selected chromosomes
(measurements from five meta-
phases, lower/upper thresholds
at ratios 0.85/1.15). Note both
loss of the distal region (red)
and gain of the proximal region
(green) on the short arm of
chromosome 8. Also loss on 9p
and gain on 19q can be distin-
guished. Chromosome 17 dis-
plays losses on both arms, most
likely caused by loss of a
whole chromosome (see inter-
phase cytogenetics: Figs. 1b,
c). b Prostate cancer (bone me-
tastasis): CGH of an archival,
formation-fixed, paraffin-em-
bedded bone metastasis of
prostate adenocarcinoma (same
as Fig. 1). Again, the chromo-
somal ideograms are shown to-
gether with the ratio profiles
and the digitized fluorescent
images of four selected chro-
mosomes (measurements from
seven metaphases, lower/upper
thresholds at ratios 0.80/1.20).
Gain is seen of 8q and on 10q,
whereas losses can be detected
on 8p, on 13q and of chromo-
some Y (compare ISH data in
Fig. 1f). The gain of 8q in-
volves the entire chromosome
arm, while in Figs. 1d and e a
gain of the chromosome 8 cen-
tromere was disclosed by inter-
phase cytogenetics. This
strongly suggest the presence
of an isochromosome of the
long arm of chromosome 8 &/fig.c:
Y and aneuploidy for chromosome 1 reached high preva-
lences in high-grade dysplasia and adenocarcinoma.
Hunter et al. (1993) observed absence of the Y chromo-
some in 62% of SCCs of the esophagus. A preliminary
CGH study by our group disclosed frequent gain of 8q
and chromosome 20, as well as loss of 8p, 9p, 16, and 17
sequences in adenocarcinomas (C. Rosenberg and H. van
Dekken, unpublished results).
Colorectal cancer
Colorectal adenocarcinomas arise, in general, in adeno-
matous polyps. Cajulis and Frias-Hidvegi (1993) showed
gain of chromosome 8 in one out of three fine-needle as-
pirates from colon adenocarcinomas. FISH applied to
single-cell suspensions of 35 colonic adenomas revealed
trisomy of chromosome 7 in over one-third of cases
(Herbergs et al. 1994). In nearly half of the cases, this
aberration was combined with abnormalities of the other
chromosomes investigated. ISH applied to 23 archival
advanced stage colon cancer specimens, revealed three to
eight copies of chromosomes 8, 12, and 17 (Steiner et al.
1993). The mean frequency of multiple copies for chro-
mosome 12 was significantly greater than that for chro-
mosome 17. Chen and Nierman (1994) used chromo-
some painting by FISH with library probes to examine
abnormalities identified by G-banding in two colon can-
cer cell lines, DLD-1 and HCT-15. Trisomy of chromo-
some 20 and trisomy of the 2p13–p23 segment were seen
in the DLD-1 cell line, whereas in HCT-15, a t(16;16)
and gain of Y were seen. Recently, Sasaki et al. (1995)
demonstrated monosomy of chromosome 18 in one-third
of cases using FISH on suspensions derived from early
carcinomas without foci of adenoma. Suspensions de-
rived from more advanced cancers showed monosomy
18 in 44% of cases.
In addition to these ISH data, CGH revealed gain of
chromosomes 7, 13, and 20q, whereas loss was seen of
9p, 17, and 18 (Schlegel et al. 1995). Ried et al. (1996)
identified gain of 7 in low-grade adenomas, whereas in
high-grade adenomas gain of chromosome 20 also oc-
curred. Further, the transition from adenoma to carcino-
ma was characterized by multiple additional alterations,
such as loss of 18q or gain of 8q.
Prostate cancer
The vast majority of prostatic cancers are adenocarcino-
mas. Many studies have been reported concerning (F)ISH
to nuclear suspensions and paraffin sections of prostatic
cancer. Numerical aberrations of chromosomes 7, 8, 10,
16, 17, 18, and Y were revealed (van Dekken et al.
1990b; van Dekken and Alers 1993; Baretton et al. 1994;
Brown et al. 1994; Henke et al. 1994; Jones et al. 1994;
Visakorpi et al. 1994; Zitzelsberger et al. 1994; Alers et
al. 1995a). Furthermore, FISH studies of nuclear suspen-
sions or touch imprints of prostatic tumors revealed that
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(Tsuji et al. 1994). The copy number of chromosome 17
significantly increased in oral malignant tumors compared
to benign tumors. Worsham et al. (1995) demonstrated re-
arrangements of Y and aneuploidy in two synchronously
arising primary squamous cell carcinomas (SCCs) and
their recurrences. Moreover, these authors concluded that
the FISH patterns and the presence of a clonal Y marker
in all four tumor samples indicate a monoclonal origin of
the synchronous primaries and their recurrences. Recently,
Lese et al. (1995) visualized INT2 and HST1 amplifica-
tion in oral SCCs, containing HSRs, by dual-color FISH
with cosmid probes specific for the chromosome 11q13
region. Non-isotopic ISH on paraffin-embedded tissue
sections of 25 HNSCCs using centromere probes specific
for chromosomes 7 and 17, revealed polysomy in both
premalignant and tumor tissue (Voravud et al. 1993).
Moreover, the frequency of cells with polysomy increased
as the tissues passed from histologically normal epitheli-
um to hyperplasia to dysplasia to cancer.
A CGH analysis of 13 primary HNSCCs by Speicher
et al. (1995) showed a frequent copy number increase on
chromosome regions 3q and 5p and less frequently on
1q. Loss occurred most frequently at 3p, 5q, 19p, and
19q. Eight sites exhibiting sequence amplification were
mapped to 3q26-qter, 11q13, 12p, 2q33–q36, 7q21–q22,
7q33-qter, 9p, and 13q23-qter. The authors suggest that
the regions 3q26-qter and 5p may harbor oncogenes im-
portant in HNSCC development. A CGH study by
Brzoska et al. (1995) of ten HNSCCs also identified gain
of the chromosome 3q26–q27 region and loss of chro-
mosome 3p at high frequency (over 50% of cases). These
findings were largely confirmed in a recent study of 30
HNSCCs (Bockmuhl et al. 1996). However, in addition
to these changes, frequent losses were seen of 1p, 8p, 9p,
and 13q, as well as frequent gains of 8q and 19.
Esophageal cancer
In the esophagus, the incidence of adenocarcinoma is in-
creasing rapidly, now equalling that of SCC. Most
esophageal adenocarcinomas arise in so-called Barrett’s
epithelium, a precancerous lesion near or at the gas-
tro–esophageal junction. ISH applied to archival tissue
sections of 14 adenocarcinomas of the esophagus using
three chromosome Y-specific DNA probes showed ab-
sence of the Y chromosome in 93% of the adenocarcino-
mas (Hunter et al. 1993). FISH on nuclear suspensions
of ten gastric adenocarcinomas also revealed loss of the
Y chromosome in a high percentage of male patients
(van Dekken et al. 1990a). In a study by our group of
four archival adenocarcinomas, loss of the Y chromo-
some, overrepresentation of chromosome 8, and loss of
chromosome 17 were observed. In two tumors, negative
for p53 protein immunohistochemistry, loss of 17 was
found (Krishnadath et al. 1994). In another study, aneu-
ploidy, as determined by ISH for chromosome 1, and
loss of Y correlated with progression from metaplasia to
dysplasia to carcinoma (Krishnadath et al. 1995). Loss of
424
Fig. 3
alterations of chromosomes 7 and 8 are potential markers
of poor prognosis in prostate cancer (Alcaraz et al. 1994;
Bandyk et al. 1994; Takahashi et al. 1994). A combined
ISH and CGH analysis showed that gain of chromosome
8 was, generally, based on isochromosome 8q formation
(J.C. Alers et al., submitted for publication). Deletion of
8p22 sequences was seen by FISH with cosmid DNA
probes (Matsuyama et al. 1994a). Likewise, Macoska et
al. (1994) showed loss of 8p22 sequences in frozen tissue
sections of prostatic tumors by FISH. Further, intratumor-
al heterogeneity for both ploidy and chromosomal aberra-
tions appeared a prominent feature of prostatic adenocar-
cinomas (Alers et al. 1995b). Another study by our group
described aneuploidy and loss of the Y chromosome in
prostatic intraepithelial neoplastic lesions adjacent to ade-
nocarcinoma (Alers et al. 1995a).
A CGH study by Cher et al. (1994) demonstrated loss
of 8p sequences in a panel of 17 prostatic tumors. Fur-
ther, 8p loss and 8q gain as detected by CGH correlated
with allelic imbalance mapping by a PCR/RFLP study. A
subsequent investigation by the same group (Cher et al.
1996) on a panel of regional lymph node and bone me-
tastases showed frequent gain of 8q, as well as loss of
8p, 10q, 13q, 16q, and 17p. Furthermore, a CGH study
of 31 primary and 9 recurrent prostatic carcinomas by
Visakorpi et al. (1995a) revealed losses of 6q, 8p, 9p,
13q, 16q, and 18q. Allelic loss studies showed a 76%
concordance with CGH results. Local recurrences that
developed during endocrine therapy showed significantly
more gains and losses of DNA sequences than primary
tumors. Gains of 8q, X, and 7, as well as loss of 8p were
particularly involved. Comparable changes were ob-
served by Joos et al. (1995). CGH also revealed that am-
plification of the chromosome X-linked androgen recep-
tor gene commonly occurs in recurrent tumors during an-
drogen deprivation therapy (Visakorpi et al. 1995b).
Bladder cancer
Carcinoma in situ or papillomas are presumed to give
rise to transitional cell carcinoma (TCC) of the bladder.
ISH of TCC has been reported frequently. A FISH study
with repetitive probes on tumor cell suspensions showed
monosomy for chromosome 9 as the most frequently oc-
curring abnormality, followed by trisomy for chromo-
somes 1, 7, and 11 (Hopman et al. 1991). The data sug-
gested that loss of chromosome 9 may be an early event
in the development of bladder cancer, while aberrations
involving chromosomes 1 and 7 may be important in tu-
mor progression. Waldman et al. (1991) demonstrated in
a FISH study on touch preparations of TCCs, monosomy
of chromosome 9, as well as overrepresentation of chro-
mosomes 7 and 11. Matsuyama et al. (1994b) performed
double-target ISH on 37 cases of bladder cancer. Tri-
somy 7, monosomy 9, and trisomy 10 were detected
most frequently. In a study by Poddighe et al. (1992),
structural aberrations of chromosome 1 were examined
in nuclear suspensions of TCC by FISH with a combina-
tion of centromeric (1q12), telomeric (1p36), and library
DNA probes. Meloni et al. (1993) demonstrated that
FISH analysis on urine and bladder washings is a very
useful tool in the diagnosis, early detection, and clinical
management of bladder cancer. Sauter et al. (1993)
showed heterogeneity in amplification of the erbB-2 on-
cogene in a small number of cases by dual-labelling
FISH with a centromeric probe for chromosome 17 and a
cosmid probe for the erbB-2 locus. The suitability of
both conventional karyotyping and FISH in the detection
of intratumoral heterogeneity in bladder cancers was in-
vestigated by Schapers et al. (1993). More recently,
Sauter et al. (1994) examined single-cell suspensions
from 106 formalin-fixed bladder cancers, as well as
touch imprints of 45 fresh bladder tumors, by FISH with
probes for the centromeric region of chromosome 17 and
a cosmid for the p53 locus on 17p13.1. Double-hybrid-
ization experiments showed an increment in the percent-
age of 17p deletions with advancing tumor stage. Dele-
tion of 17p was also highly correlated with tumor grade
and with p53 immunostaining. Similarly, FISH with a
p53-specific probe was applied to cell suspensions of a
panel of 42 TCCs by Matsuyama et al. (1994c). In 64%
of the specimens, p53 deletion was seen, whereas 38%
showed overexpression at the immunohistochemical lev-
el.
A CGH study of 26 mainly high-grade, high-stage
TCCs by Kallioniemi et al. (1995) showed losses affect-
ing chromosomes 3p, 8p, 9, 11p, 11q, 17p, and 12q.
Gains of DNA sequences were most often found at chro-
mosomal regions distinct from locations of currently
known oncogenes. Additionally, a CGH study of 14 low-
and high-grade/stage TCCs (Voorter et al. 1995) revealed
other regions of amplification. Imbalances involved loss-
es of chromosomes 5, 9, and 11. In half of the cases, loss
detected by CGH was also detected by RFLP studies.
Kidney cancer
Renal cell carcinomas (RCCs) are, in general, adenocar-
cinomas. FISH has been performed with yeast artificial
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Fig. 3a–f Interphase ISH of precursor lesions of human epithe-
lial cancers. a–c Barrett’s esophagus. a ISH with the chromo-
some 17-specific centromeric DNA probe to a routinely pro-
cessed, formalin-fixed, paraffin-embedded section of dysplastic
Barrett’s esophagus. Most epithelial cell nuclei show two ISH
spots; a few aneusomic nuclei can be seen (one is arrowed). b
Same area, ISH with a 17p13 cosmid DNA probe. Most epithelial
nuclei display one ISH spot, indicating loss of this chromosomal
region. c Same area, p53 immunohistochemistry with monoclonal
DO-7 reveals many darkly stained nuclei, indicating overexpres-
sion of the p53 protein. These data suggest loss of one p53 gene
with mutation of the other. d–f Prostatic intraepithelial neoplasia
(PIN). d Hematoxylin-eosin stained section, showing a PIN le-
sion (P), surrounded by prostatic cancer cells (T). e Detail (left
part of the PIN). ISH with the chromosome Y-specific DNA
probe, illustrating loss in the luminal cells (arrows), whereas the
basal cells have retained this chromosome (arrowheads). f Same
area. ISH with the chromosome 1 DNA probe, demonstrating a
normal hybridization pattern in the PIN cells. A 40× objective
was used, except for d (20×) &/fig.c:
s
chromosomes to identify the position of translocation
breakpoints (t3;6) and t(3;8) in familial RCC by a number
of groups (e.g., Wilke et al. 1994). A FISH study on a
small panel of disaggregated archival RCC tissue speci-
mens showed numerical aberrations of chromosomes 1, 7,
17, and Y (Wolman et al. 1993). Abnormal copy numbers
of chromosomes 1 and/or 17 in seven out of nine cases
had not been identified by previous karyotyping. Beck et
al. (1995) performed FISH on single-cell suspensions of
37 RCCs. Numerical aberrations of chromosomes 1
and/or chromosome 7 were present in 18 RCCs, and five
of these cases showed monosomy for chromosome 1 in
more than 50% of the tumor cells. Section ISH using a
large probe set showed that chromosomes 1, 3, 7, and 17
have a higher propensity for aneuploidy than chromo-
somes 8, 10, 11, 12, and 16 (El-Naggar et al. 1994). Fur-
ther, these results correlated with DNA flow cytometry.
CGH in chromophobe RCC, a subtype of RCC,
showed specific loss of chromosomes 1, 2, 6, 10, 13, 17,
and 21 (Speicher et al. 1994). Moch et al. (1996) found a
correlation of genetic changes with clinical outcome.
Losses were most prevalent at 3p, 9p, and 13q. Gains
were most frequently seen of 5q and 7. The same group
found a high degree of concordance between CGH and
allelotyping (Presti et al. 1996). Recently, the involve-
ment of 1q gain and 3p loss in metastatic tumor progres-
sion was described (Gronwald et al. 1997).
Breast cancer
Breast cancer comprises ductal and lobular adenocarci-
nomas, each having a specific precancerous defect, i.e.,
ductal (DCIS) and lobular carcinoma in situ (LCIS). A
considerable number of ISH studies has been published,
most often on ductal-type breast carcinoma. Devilee et
al. (1988) showed numerical aberrations of chromosome
1 and/or 18 in six out of seven primary breast tumors by
performing FISH with centromeric probes. Matsumura et
al. (1992) visualized only one copy of a 17p13.1 cosmid
DNA probe in nuclei with loss of heterozygosity (LOH)
at the 17p13.3 region, whereas nuclei without LOH at
that locus showed no deletions by FISH. Microdissection
followed by FISH was used to identify chromosomal
HSRs (Meltzer et al. 1992; Guan et al. 1994). The results
indicated amplification of regions 17q12 (erbB-2 re-
gion), 13q21, and 20q12–13.2. Balazs et al. (1995) in-
vestigated karyotypic heterogeneity in touch prepara-
tions of 23 breast cancers by FISH. Every tumor ana-
lyzed showed a heterogenous distribution for at least one
chromosome. Micale et al. (1994) revealed gain of chro-
mosome 1 by FISH applied to tissue sections of breast
cancers and hyperplastic lesions. Interestingly, aneuploi-
dy for several chromosomes was also seen in the hyper-
plastic tissue. FISH with a chromosome 17 centromeric
probe showed polysomy of chromosome 17 in non-inva-
sive DCIS (Murphy et al. 1995). Further, erbB-2 amplifi-
cation was seen in both the invasive and non-invasive
components within a breast cancer biopsy. Recently,
chromosome 1 aneusomy was identified on archival tis-
sue sections of 16 DCISs (Harrison et al. 1995). The au-
thors concluded that chromosome 1 aneusomy precedes
invasion and that it is a relatively consistent occurrence
in high-grade lesions.
CGH applied to 15 breast cancer cell lines and 33 pri-
mary tumors showed increased DNA sequences in two-
thirds of primary tumors and almost all cell lines (Ka-
llioniemi et al. 1994). Most of these amplified loci were
distinct from those of currently known amplified genes
in breast cancer, with sequences originating from
17q22–q24 and 20q13 displaying the highest frequency
of amplification. Several amplifications, including the
ones described above, were observed by Muleris et al.
(1994). A study by Ried et al. (1995) showed copy num-
ber increases of chromosome 1q and 8q sequences. Loss
was seen for chromosome 17p and 22. Interestingly,
Isola et al. (1995) demonstrated that increased copy
numbers of chromosomes 8q and 20q13 correlated with
recurrence rate in node-negative breast cancer and there-
fore may confer a more aggressive phenotype. Recently,
CGH of DCIS revealed gains of 1q, 17q, 19q, and 20q,
losses were seen of 13q, 14q, 16q, 17p, and 22q (James
et al. 1997). Chromosomal alterations appeared more
frequently in higher grades of DCIS.
Ovarian cancer
Ovarian carcinomas represent a heterogeneous group of
tumors, most of them being papillary adenocarcinomas. A
recent interphase cytogenetics study by Liehr et al. (1994)
revealed specific loss of chromosomes 17 and 20, and gain
of chromosomes 1, 7, 8, and 11. Persons et al. (1993) per-
formed FISH with centromeric probes to touch prepara-
tions of 25 epithelial ovarian tumors. They showed rela-
tive loss of chromosomes 17 and X, as well as a relative
gain of chromosomes 12 and 8. Additionally, they showed
the HER-2/neu gene to be amplified in 2 of the 25 tumors.
Chromosome microdissection followed by FISH was used
to identify the chromosomal origin of amplified regions in
HSRs of seven ovarian carcinomas (Guan et al. 1995).
The results showed that 12 specific chromosome regions
are amplified, including 11q, 12q, 16p, 19p, and 19q.
These regions may harbor genes important in ovarian can-
cer tumorigenesis. Recently, gains of chromosomes 6 and
7 were seen in borderline tumors, a presumed precursor
condition of ovarian carcinoma (Diebold et al. 1996).
CGH of invasive ovarian cancers revealed, most impor-
tantly, gain of 3q and 8q sequences, loss was found most
frequently of 16q and 17 (Iwabuchi et al. 1995). The over-
all concordance between concurrently performed LOH
and reduced copy number by CGH was 84%.
Discussion and conclusion
It can be stated that interphase hybridization technology
has emerged as an important instrument for the delinea-
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tion of genetic changes in human solid cancers. Results
from molecular and karyotyping studies could be con-
firmed in situ and, in addition, new genetic aberrations
are being disclosed. For example, in lung cancer
(NSCLC), FISH with region-specific probes showed loss
of the p15/p16 region at 9p, which is consistent with
LOH studies. In head and neck tumors (HNSCC), CGH
studies repeatedly identified a new amplified chromo-
somal region, 3q26-qter. This region has not been de-
scribed before, and may harbor a new oncogene impor-
tant in HNSCC development. ISH on colon cancer speci-
mens has confirmed the presence of numerical and struc-
tural aberrations frequently encountered in colorectal tu-
mors, such as trisomy 7 and monosomy 18. It has also
added some new numerical aberrations, e.g., gain of
chromosome 12. Additionally, CGH of adenomas re-
vealed gains of chromosome 7 and 20. In prostatic ade-
nocarcinoma, ISH analyses have confirmed chromosom-
al abnormalities that had been previously detected by
karyotyping and LOH studies. However, they appear at
much higher frequency than was previously suspected
from conventional cytogenetic analysis (e.g., loss of Y
and alterations of chromosome 8). Additionally, ISH
analysis rendered possible markers for the biological ag-
gressiveness of prostatic tumors, such as gain of chromo-
somes 7 and 8. CGH also provided some new regions of
interest, most notably the amplification of the 8q arm.
This is, most likely, the result of isochromosome 8q for-
mation, which is illustrated by a combined ISH/CGH ef-
fort in Figs. 1 and 2. In bladder cancer, CGH studies
have confirmed some sites of allelic loss, as, for in-
stance, loss of 11p, and have added some interesting new
chromosomal regions of amplification. FISH studies of
breast cancers with region-specific probes for the
17p13.1 (p53) region and the 13q14 (Rb) region were in
concordance with LOH studies. FISH was also used to
identify the origin of HSRs, a frequently seen abnormali-
ty in this type of cancer. One of the amplified oncogenes
is the erbB-2 gene on 17q12. Another, yet unknown, re-
sides in the 20q12–13 region, a site that was revealed by
CGH analysis. The latter technique also distinguished
frequent alterations in DCIS, the precursor of invasive
ductal carcinoma.
In conclusion, ISH and CGH have established their
importance in solid cancer genetics and will continue to
gain momentum in this area of research. Microdissection
technology (Zhuang et al. 1995) will yield further access
to analysis of small tissue areas, which is especially im-
portant for CGH studies of precancerous lesions. Fur-
thermore, the increasing and continuing availability of
new types of DNA probes, such as phage and bacterial
artificial chromosomes (Monaco and Larin 1994), will
facilitate the in situ detection of possibly important ge-
netic sites.
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